Natera, Inc. Common Stock (NTRA)
Natera, Inc. is a biotechnology company specializing in genetic testing and diagnostics. It develops and offers advanced cell-free DNA testing services for reproductive health, oncology, organ transplant monitoring, and rare disorders. Natera's innovative approach includes non-invasive prenatal testing (NIPT) and other laboratory-based genetic assays to help clinicians and patients make informed medical decisions.
Company News
The global liquid biopsy market is projected to grow from $4.03 billion in 2025 to $7.05 billion by 2030, driven by rising cancer incidence, precision medicine advancements, and technological innovations in early disease detection.
Personalis reported Q2 2025 financial results with revenue falling 24% year-over-year to $17.2 million, missing estimates. Despite financial challenges, the company saw a 59% increase in clinical test volumes for its NeXT Personal platform, with promising cancer detection research.
Natera's President and Chief Business Officer, John Fesko, has sold a portion of his company shares worth over $57,000 to meet tax obligations related to the vesting of restricted stock units. The transaction reflects changes in insider ownership of the company's stock.
Smart Beta ETF report for FBT
Natera (NASDAQ:NTRA) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Ind...